Background. Medication adherence in haemodialysis patients is often challenging due to a high pill burden, complex and dynamic medication regimens and limited patient self-interest in care. The purpose of this study was to investigate the time within target INR and safety profile of thrice weekly warfarin administration in haemodialysis patients with a clinical indication for anticoagulation and documented nonadherence to medications. Methods. Thirty-seven patients from two haemodialysis units in Winnipeg, Manitoba, Canada, were recruited, and 17 patients were treated with thrice weekly warfarin and compared to 20 patients treated with daily warfarin therapy. The patients were followed for 1 year with weekly international normalized ratio (INR), dosage and adverse events recorded. The primary outcome was percentage of time with INR in target and sub (<1.5)-and supra (>4)-therapeutic INR. Adverse events were recorded in the two groups.
Introduction
The utilization of anticoagulants and/or antiplatelet agents in haemodialysis patients is high. In the Dialysis Outcomes and Practice Patterns (DOPPS) cohort, 26.7% were on warfarin, ASA and/or clopidogrel despite little evidence to support their usage [1] . In addition, bleeding may occur more frequently and with greater severity in these patients compared to the general population leading to significant morbidity and mortality [2, 3] . Warfarin inhibits the enzyme vitamin-K-epoxide reductase leading to a decrease in the reduced form of vitamin K, a key requirement for the gamma carboxylation of the clotting factors [4] . There is a high level of variability in dosing and responsiveness to the drug. This is due to intrinsic patient factors such as genetics, age, weight, liver function and ethnicity or extrinsic factors such as drug interactions, diet or adherence with the medication as prescribed [5] . Lastly, warfarin has a biological half-life of 36-42 h allowing for potential prolongation of dosing intervals [6, 7] .
Nonadherence rates are high in the haemodialysis population with pill burden, complex and dynamic of medication regimens and patient motivation all being pertinent factors [8] . In an attempt to improve adherence rates, medications such as lisinopril and atenolol have been successfully administered thrice weekly with haemodialysis [9, 10] .
The purpose of this study was to investigate the time within the target international normalized ratio (INR) and safety profile of thrice weekly warfarin administration in haemodialysis patients with a clinical indication for anticoagulation and a history of nonadherence.
Methods

Study design, population and laboratory samples
The study period was from 1 November 2007 to 30 November 2008. A total of 37 patients were recruited from two haemodialysis units in Winnipeg, Manitoba. All patients who had a clinical indication for warfarin therapy, as determined by their attending nephrologist, and were on warfarin therapy were included in the study (38/318 haemodialysis patients in total). Patients selected for thrice weekly warfarin treatment had a demonstrated history of nonadherence to prescribed medication at the attending nephrologists discretion. Nonadherence was defined as a history of a dementing illness and incompetence to make one's own medical decisions, a consistent history of warfarin dosing errors (failure to take warfarin dose greater than three times) and/or current alcohol or drug abuse. Adherence was monitored weekly in the daily warfarin group. A total of 17 patients on thrice weekly warfarin were compared to a control group of 20 haemodialysis patients on daily warfarin therapy. Patients in the thrice weekly warfarin group were enrolled or converted from daily warfarin dosing during the 1-year study period and thereby were on treatment for a shorter duration (487 treatment weeks and 834 treatment weeks in the thrice weekly and daily dosage groups, respectively). All patients were dialysed three times a week in-centre for 4 h per session using an OF160 or OF200 high flux dialyser. Average Kt/V was calculated as the average of the monthly single pool Kt/V measurement for each patient. Patients were considered for inclusion in the study if they were >18 years of age, had a clinical indication for anticoagulation and had an INR target of 2-3. Patients were excluded if they received dialysis therapy outside of Manitoba, and had a mechanical valve or a hypercoaguable state. The study was approved by the University of Manitoba and St Boniface Hospital Ethics board. Patient baseline demographics, time on dialysis, cause of end-stage renal disease (ESRD), comorbidities, medications and vascular access were collected retrospectively by chart review (see Table 1 ). The Charlson comorbidity index has been validated in the ESRD population and was determined for each patient [11] . Blood samples for the measurement of the INR were performed weekly and a once weekly warfarin dosage adjustment made by the attending nephrologist as deemed necessary. INR was determined by using Innovin thromboplastin (Dade International Inc., Deerfield, IL, USA) with an international sensitivity analysis of 1.03 for the entire study period. To assess the stability of the INR on non-dialysis days, study patients receiving thrice weekly warfarin underwent INR measurements for 3 consecutive days (spanning 2 dialysis days and 1 nondialysis day) mid-week for 2 consecutive weeks. The INR measurement was performed before haemodialysis as per standard practice in our unit.
In patients newly started on warfarin, to allow for a dosage titration and achievement of steady state, the first 2 weeks of INR values were excluded from analysis. All patients were treated with heparin 1000 unit bolus followed by 1000 units/h infusion during haemodialysis.
The primary endpoint was comparison of the percentage of time patients had an INR in target range of 2-3. Specifically, the time patients were in target INR was determined by the number of weekly INR measurements between 2 and 3 over total weeks exposed to warfarin. Secondary outcomes included the percentage of time patients had an INR in sub-therapeutic (INR<1.5) and supra-therapeutic range (>4), INR distribution on non-dialysis days and adverse bleeding events. All adverse bleeding events were recorded during the study period and categorized as minor (no packed red cell transfusion required, no hospitalization) or major (need for hospitalization, requirement of a blood transfusion, intracranial haemorrhage, retroperitoneal haemorrhage or haemorrhage resulting in death).
Statistical analysis
Categorical variables were analysed using the chi-square test and continuous variables with unpaired t-tests. Descriptive statistics were calculated. Average values for INR and warfarin dose were calculated per patient, and then reported as a median for the entire cohort. A P-value <0.05 was considered statistically significant. The percentage of INR values within target of 2-3 were determined and compared between the two groups. All analyses were performed using SPSS v16. Table 1 outlines the demographic, clinical characteristics, relevant medications and indications for anticoagulation in 37 patients. Of the 37 total study patients, 20 took warfarin daily (834 patient weeks of observation) and 17 took it after their in-centre haemodialysis session, three times weekly (487 patient weeks observation). Glomerulonephritis was the primary aetiology of renal failure in the daily group (nine patients) while diabetes was the major cause in the thrice weekly group (six patients). A significant proportion of the population was dialysed via a central venous catheter [8/17 (47%) and 12/20(60%)]. The Charlson comorbidity index was significantly different between the two groups (thrice weekly group 6.35 ± 1.77 versus 4.55 ± 1.64 in the daily group, P = 0.003). A total of 17 patients were on either ASA and/or clopidogrel with a slightly higher number in the thrice weekly group (10 versus 7 patients, P = NS). The most common indication for anticoagulation was atrial fibrillation in 20 patients (12 in the daily and 8 in the thrice weekly group).
Results
Figures 1-4 are box plots depicting the dosage and INR distributions between the two groups. The mean warfarin dose in the daily group was 3.22 ± 1.28 mg with a maximum dose of 11 mg/day versus a mean dose of 8.19 ± 5.77 mg, and a maximum dose of 28 mg per dialysis in the thrice weekly group (P < 0.001). The mean weekly warfarin dosage was 23 ± 12 mg in the daily dosage group and 26 ± 19 mg in the thrice weekly group (P = 0.004). Figures 2 and 3 depict the individual patient INR variation over the 13-month study period in both groups. Figure 4 depicts the INR distribution of the two populations. In the thrice weekly group, the mean INR was 2.2 ± 0.18 compared to the mean INR of 2.3 ± 0.25 in the daily group (P = NS). A non-dialysis day INR measurement was made to ensure that patients were not exposed to wide fluctuations in anticoagulation levels and to quantitate the degree of variability. A total of 24 sets of 3 consecutive day INR measurements were made on consecutive days. Days 1 and 3 were hemodialysis days on which a dose of warfarin was to be administered. Day 2 was an off day on which no warfarin was administered, but an INR was still measured. The mean INR on Days 1, 2 and 3 with standard deviation was 2.1 ± 0.34, 2.2 ± 0.47 and 2.15 ± 0.39, respectively (P = NS). Table 2 shows that the thrice weekly group was at target INR (2-3) 56.9% versus 49.3% (the chi-square test, P = 0.008) of the time in those prescribed warfarin daily. To assess whether patients were exposed to clinically significant sub-therapeutic and supra-therapeutic levels of anticoagulation, INRs of <1.5 or >4 were examined. Patients experienced sub-therapeutic values 14.6-16% of their time on warfarin with no statistically significant difference between the two groups. Supra-therapeutic INRs occurred less frequently in the thrice weekly versus daily group (2.7 versus 4.3%; P = 0.025).
Adverse events are reported in Table 3 . Overall adverse event rates were 0.44 and 0.64/patient year on warfarin, while major bleeding events were not significantly different between the groups (0.19 and 0.21/patient year on warfarin). One death occurred due to intracranial haemorrhage in the thrice weekly group. There was no significant increase in bleeding events in patients on antiplatelet therapy. No patients suffered a thrombotic event during the study period.
Discussion
This study demonstrated that achievement of target levels of anticoagulation with thrice weekly warfarin administration compared with daily warfarin therapy (56.9 versus 49.3% in target, P = 0.008, respectively) appears safe and feasible. To our knowledge, this is the first study investigating thrice weekly dosing of warfarin in the dialysis population.
Previous studies have demonstrated high rates of medication nonadherence in dialysis patients with rates ranging from 19 to 99%, with 14% of patients citing 'the number of medications' as a major reason for their noncompliance [8, 12, 13] . Furthermore, noncompliance with the dialysis regimen is associated with an increase in mortality [14, 15] . Strategies to reduce pill burden and overcome nonadherence have been successfully implemented in the treatment of hypertension in haemodialysis with thrice weekly lisinopril and atenolol reducing blood pressure by 12-22/11 mmHg [9, 10] . In our study, patients were deemed nonadherent by the attending nephrologists based on failure to take warfarin as prescribed due to a history of self-administered medication dosage errors, often due to cognitive impairment. In-centre administration in carefully selected cases could ensure that adequate anticoagulation is achieved while limiting medication over dosage.
The thrice weekly dosing regimen showed similar INR variability, higher percentage of time within targets and less time with INR >4 versus daily dosage. This occurred despite the broader dosage ranges in the thrice weekly group (1-28 mg/haemodialysis versus 1-11 mg/day). Although the dosage range is broad in the thrice weekly group, the total weekly dosage is only slightly higher in the thrice weekly group (23 ± 12 mg in the daily dosage group versus 26 ± 19 mg in the thrice weekly group, P = 0.004). Up to 10-fold, interindividual variability in warfarin dosing has been reported [16] . Better achievement of INR targets with the thrice weekly strategy was also apparent despite the larger burden of comorbidity as measured by the Charlson comorbidity index in that group. This is likely due to nonadherence being highly collinear with comorbidity. Previous studies in the non-dialysis population have reported comparable percentages of time within target varying from 55 to 64% versus 49 to 56.9% in our population [17, 18] . Reasons for this discrepancy could include higher rates of subclinical vitamin K deficiency, hypoalbuminaemia and acute illness in the dialysis population [19, 20] . The amount of time required for warfarin to inhibit coagulation factors is variable ranging from 5-7 days with early inhibition of proteins C and S (24-48 h) leading to a transient hypercoaguable state followed by a full anticoagulant affect by inhibition of factors II, VII, IX and X [6, 19, 21] . The duration of anticoagulation after discontinuation of warfarin is dependent on the regeneration of the carboxylated form of the vitamin K-dependent clotting factors that may be delayed or impaired in dialysis patients [20] . Furthermore, the haemodialysis population is routinely exposed to varying dosages of heparin and the uraemic milieu itself, which has known inhibitory effects on the coagulation pathway [21] . The interplay between these multiple factors may be what allows a thrice weekly warfarin dosing strategy to effectively lead to anticoagulation.
Adverse events occurred in 35% of our total population with major bleeding events occurring in 2/20 (10%) and 3/17 (18%) patients in the daily dosed and thrice weekly dosed groups, respectively. This corresponded to a major bleeding rate of 0.19/patient year on warfarin for the daily group and 0.21/patient year on warfarin for the thrice weekly group. One patient in the thrice weekly group died of an intracranial haemorrhage. This patient had a history of poorly controlled hypertension as a result of documented medication nonadherence. Despite being at high risk for an adverse bleeding event, the anticoagulation was required for an acute venous thrombosis. Many of the events were relatively minor events such as epistaxis, dental and vaginal bleeding, haematuria and a breast haematoma. The number of major bleeding events occurring in our population was lower than the major bleeding rates of 0.26-0.54/patient year of exposure found by Elliot et al. in a systematic review [2] . Yearly, major bleeding rates for anticoagulated patients have been reported in ranges from 3.1 to 54% in other ESRD populations with the risk increasing in patients on concurrent antiplatelet agents and comorbid illnesses [2, 3, 5, 7] . In our study, 7/20 (35%) and 10/17 (59%) patients in the daily dosed and thrice weekly groups were on antiplatelet agents. The overall adverse event rates of 0.44 and 0.64/patient year in the daily and thrice weekly groups were higher than expected. This could be due to the high burden of comorbid illness in our study, high rates of antiplatelet agent use or due to a chance finding due to our small population size. Overall, our rates of major bleeding were comparable to similar, previously reported ESRD cohorts.
The key limitations to our study are the small sample size and the non-randomized design. The study was not powered to detect differences in bleeding risk, and adjustment for differences in baseline comorbidities is not possible. Nevertheless, our results do support the feasibility of thrice weekly dosing, and suggest that an RCT would be safe and worthwhile.
In conclusion, we report that thrice weekly dosing of warfarin in haemodialysis patients with documented medication nonadherence results in increased time in therapeutic target with fewer episodes of supra-therapeutic INR values compared to daily dosage warfarin therapy. We observed no significant difference in bleeding risk. A randomized controlled trial of thrice weekly warfarin is warranted.
